# Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

> **NCT03605056** · PHASE2 · UNKNOWN · sponsor: **Peng Liu** · enrollment: 25 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** chidamide
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT03605056
- **Lead sponsor:** Peng Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-31
- **Primary completion:** 2020-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2018-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605056, "Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03605056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*